Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Gemcitabine and Docetaxel with Radiation Therapy before Surgery for the Treatment of High Grade and Greater than 5 cm Soft Tissue Sarcoma of the Extremities

Trial Status: temporarily closed to accrual

This phase I trial investigates the side effects and best dose of gemcitabine and docetaxel when given together with radiation therapy, and to see how well the combination works before surgery in treating patients with high grade soft tissue sarcoma of the upper or lower limbs (extremities) that is over 5 cm in size. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving gemcitabine, docetaxel, and radiation therapy to patients with soft tissue sarcoma of the extremities may lead to a reduction in the size of the tumor prior to surgery. It may also lead to better surgical outcomes and/or reduce the risk of the tumor spreading to other parts of the body.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.